Cancer Genetics Shares Down 7.1% After Earnings Miss (CGIX)
Cancer Genetics (NASDAQ:CGIX) traded down 7.1% during trading on Thursday after the company announced weaker than expected quarterly earnings, Stock Ratings News reports. The company traded as low as $9.01 and last traded at $9.15, with a volume of 72,296 shares. The stock had previously closed at $9.85.
The company reported ($0.50) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.37) by $0.13. The company had revenue of $3.20 million for the quarter, compared to the consensus estimate of $2.13 million.
A number of research firms have recently commented on CGIX. Analysts at Cantor Fitzgerald reiterated a “buy” rating on shares of Cancer Genetics in a research note on Thursday. They now have a $25.00 price target on the stock, down previously from $30.00.
The stock has a 50-day moving average of $10.4 and a 200-day moving average of $13.77. The company’s market cap is $85.2 million.
Cancer Genetics, Inc (NASDAQ:CGIX) is an early-stage, diagnostic company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.